一分钟看懂
这是一项关于癌的III 期研究，登记的药物或干预包括Vepugratinib；Placebo；EV；Pembrolizumab，当前状态为招募中。登记地点显示中国北京、长春、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Vepugratinib；Placebo；EV；Pembrolizumab · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital · 北京
- Peking University Third Hospital · 北京
- Beijing Cancer hospital · 北京
- Beijing GoBroad Hospital · 北京
- The First Hospital of Jilin University · 长春
- Xiangya Hospital Central South University · 长沙
- Hunan Cancer Hospital · 长沙
- West China Hospital, Sichuan University · 成都
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- Chongqing University Cancer Hospital · 重庆
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Zhujiang Hospital · 广州
- Sun Yat-Sen University Cancer Centre · 广州
- Zhejiang Provincial People's Hospital · 杭州
- Sir Run Run Shaw Hospital · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School · 南京
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Ningbo First Hospital · 宁波
- Renji Hospital Shanghai Jiao Tong University School of Medicine · 上海
- Huashan Hospital, Fudan University · 上海
- Shanghai Tenth People's Hospital · 上海
- The Second Hospital of Tianjin Medical University · 天津
- Tongji Hospital Tongji Medical,Science & Technology · 武汉
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
- * Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
- * Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- * Have adequate laboratory parameters
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07218380；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。